Comparing predictors of conversion and decline in mild cognitive impairment
- PMID: 20592257
- PMCID: PMC2906178
- DOI: 10.1212/WNL.0b013e3181e8e8b8
Comparing predictors of conversion and decline in mild cognitive impairment
Abstract
Objective: A variety of measurements have been individually linked to decline in mild cognitive impairment (MCI), but the identification of optimal markers for predicting disease progression remains unresolved. The goal of this study was to evaluate the prognostic ability of genetic, CSF, neuroimaging, and cognitive measurements obtained in the same participants.
Methods: APOE epsilon4 allele frequency, CSF proteins (Abeta(1-42), total tau, hyperphosphorylated tau [p-tau(181p)]), glucose metabolism (FDG-PET), hippocampal volume, and episodic memory performance were evaluated at baseline in patients with amnestic MCI (n = 85), using data from a large multisite study (Alzheimer's Disease Neuroimaging Initiative). Patients were classified as normal or abnormal on each predictor variable based on externally derived cutoffs, and then variables were evaluated as predictors of subsequent conversion to Alzheimer disease (AD) and cognitive decline (Alzheimer's Disease Assessment Scale-Cognitive Subscale) during a variable follow-up period (1.9 +/- 0.4 years).
Results: Patients with MCI converted to AD at an annual rate of 17.2%. Subjects with MCI who had abnormal results on both FDG-PET and episodic memory were 11.7 times more likely to convert to AD than subjects who had normal results on both measures (p <or= 0.02). In addition, the CSF ratio p-tau(181p)/Abeta(1-42) (beta = 1.10 +/- 0.53; p = 0.04) and, marginally, FDG-PET predicted cognitive decline.
Conclusions: Baseline FDG-PET and episodic memory predict conversion to AD, whereas p-tau(181p)/Abeta(1-42) and, marginally, FDG-PET predict longitudinal cognitive decline. Complementary information provided by these biomarkers may aid in future selection of patients for clinical trials or identification of patients likely to benefit from a therapeutic intervention.
Figures

Comment in
-
Tarot decks and PET scans: predicting the future of MCI.Neurology. 2010 Jul 20;75(3):204-5. doi: 10.1212/WNL.0b013e3181e8e91b. Epub 2010 Jun 30. Neurology. 2010. PMID: 20592256 No abstract available.
-
PET has no clothes.Neurology. 2011 Jan 4;76(1):106; author reply 106. doi: 10.1212/WNL.0b013e3181fe6f47. Neurology. 2011. PMID: 21205703 No abstract available.
References
-
- Drzezga A, Lautenschlager N, Siebner H, et al. Cerebral metabolic changes accompanying conversion of mild cognitive impairment into Alzheimer's disease: a PET follow-up study. Eur J Nucl Med Mol Imaging 2003;30:1104–1113. - PubMed
-
- Grundman M, Sencakova D, Jack CR, Jr., et al. Brain MRI hippocampal volume and prediction of clinical status in a mild cognitive impairment trial. J Mol Neurosci 2002;19:23–27. - PubMed
-
- Killiany RJ, Gomez-Isla T, Moss M, et al. Use of structural magnetic resonance imaging to predict who will get Alzheimer's disease. Ann Neurol 2000;47:430–439. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
- 1U01AG24904/AG/NIA NIH HHS/United States
- UO1 AG029213-01/AG/NIA NIH HHS/United States
- T32 NS07222/NS/NINDS NIH HHS/United States
- RC1AG035427/AG/NIA NIH HHS/United States
- R01AG029672/AG/NIA NIH HHS/United States
- 1P01 AG-19724-07/AG/NIA NIH HHS/United States
- R24 RR021992/RR/NCRR NIH HHS/United States
- P30 AG010129/AG/NIA NIH HHS/United States
- R01 G10897/PHS HHS/United States
- R01-AG16381/AG/NIA NIH HHS/United States
- P01 AG 09215-20/AG/NIA NIH HHS/United States
- 1RC2AG036535-01/AG/NIA NIH HHS/United States
- RL1NS062412/NS/NINDS NIH HHS/United States
- R01 AG022394/AG/NIA NIH HHS/United States
- U01-AG024904/AG/NIA NIH HHS/United States
- P30AG036468/AG/NIA NIH HHS/United States
- U01 AG 024904/AG/NIA NIH HHS/United States
- P01 AG 17586-10/AG/NIA NIH HHS/United States
- U01 AG10483/AG/NIA NIH HHS/United States
- R01AG031252/AG/NIA NIH HHS/United States
- R01-AG030048/AG/NIA NIH HHS/United States
- R01 AG11378/AG/NIA NIH HHS/United States
- AG024904/AG/NIA NIH HHS/United States
- U01-AG10483/AG/NIA NIH HHS/United States
- U01 AG024904-01/AG/NIA NIH HHS/United States
- U19 AG010483/AG/NIA NIH HHS/United States
- U01AG024904/AG/NIA NIH HHS/United States
- P41 RR023953/RR/NCRR NIH HHS/United States
- P01AG012435/AG/NIA NIH HHS/United States
- 1 U01 AG 024904-05/AG/NIA NIH HHS/United States
- U01 AG024904/AG/NIA NIH HHS/United States
- R01 NS031966/NS/NINDS NIH HHS/United States
- P50AG23501/AG/NIA NIH HHS/United States
- P50-AG16574/AG/NIA NIH HHS/United States
- P01AG19724/AG/NIA NIH HHS/United States
- AG11378/AG/NIA NIH HHS/United States
- K01 AG030514/AG/NIA NIH HHS/United States
- AG027859/AG/NIA NIH HHS/United States
- P50 NS053488-02/NS/NINDS NIH HHS/United States
- 9 R01AG031581-10/AG/NIA NIH HHS/United States
- 2P30AG10129/AG/NIA NIH HHS/United States
- P30 AG 10124-18/AG/NIA NIH HHS/United States
- P50 AG 16574/AG/NIA NIH HHS/United States
- AG027984/AG/NIA NIH HHS/United States
- U01 AG 06786/AG/NIA NIH HHS/United States
- R01 EB00768/EB/NIBIB NIH HHS/United States
- RC2NS069368/NS/NINDS NIH HHS/United States
- AG 024904/AG/NIA NIH HHS/United States
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous